MaaT Pharma
Developing gut microbiome therapies to improve survival for cancer patients.
MAAT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012634822 (+1 more)
- LEI:
- 969500CQQB6XUNW6CN97
- Country:
- France
- Address:
- 70 AVENUE TONY GARNIER, 69007 LYON
- Website:
- https://www.maatpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics to improve survival outcomes for cancer patients. The company focuses on modulating the immune system through innovative gut microbiome-driven therapies. Its pipeline targets severe oncology diseases and complications like graft-versus-host disease (GvHD), a frequent side effect of stem cell transplantation. MaaT Pharma leverages an integrated approach that includes an AI-powered drug development platform and versatile cGMP manufacturing capabilities. A pioneer in its field, the company was the first to advance a microbiome-based therapy into a Phase 3 clinical trial for haemato-oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 19:40 |
ISS
Inside Information / Other news releases
|
English | 193.4 KB | ||
| 2025-11-13 19:40 |
ISS
Informations privilégiées / Autres communiqués
|
French | 156.5 KB | ||
| 2025-11-05 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 162.7 KB | ||
| 2025-11-05 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 132.6 KB | ||
| 2025-11-04 07:30 |
Capital/Financing Update
Inside Information / News release on accounts, results
|
English | 109.1 KB | ||
| 2025-11-04 07:30 |
Capital/Financing Update
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 167.6 KB | ||
| 2025-10-07 07:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 930.2 KB | ||
| 2025-09-17 07:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 190.8 KB | ||
| 2025-09-17 07:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 204.2 KB | ||
| 2025-07-28 07:30 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 158.6 KB | ||
| 2025-07-28 07:30 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 106.4 KB | ||
| 2025-06-13 07:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 127.5 KB | ||
| 2025-06-13 07:30 |
Earnings Release
Inside Information / Other news releases
|
English | 151.0 KB | ||
| 2025-06-02 18:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 135.6 KB | ||
| 2025-06-02 18:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 166.2 KB |
Automate Your Workflow. Get a real-time feed of all MaaT Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MaaT Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MaaT Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-12 | N/A | Other | Sell | 8 | 60.87 EUR |
| 2024-07-11 | N/A | Other | Sell | 57 | 436.14 EUR |
| 2023-12-22 | N/A | Other | Buy | 2,940 | 14,994.00 EUR |
| 2023-12-22 | N/A | Other | Buy | 1,960 | 9,996.00 EUR |
| 2023-09-27 | N/A | Other | Buy | 500 | 3,050.00 EUR |
Peer Companies
